SEC Form 4 · accession 0000899243-18-028348
MyoKardia Inc · MYOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anastasios Gianakakos
Officer — President and CEO · Director
Period of report
Oct 31, 2018
Accepted (ET)
Nov 6, 2018 · 7:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001552451
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 31, 2018 | A | 138 | $42.16 | A | 75,087 | D | |
| Common StockF2 | Nov 5, 2018 | M | 3,000 | $1.5068 | A | 78,087 | D | |
| Common StockF3 | Nov 5, 2018 | S | 500 | $55.26 | D | 77,587 | D | |
| Common StockF4 | Nov 5, 2018 | S | 2,300 | $56.7775 | D | 75,287 | D | |
| Common StockF5 | Nov 5, 2018 | S | 200 | $57.49 | D | 75,087 | D | |
| Common Stock | holding | — | — | — | 85,973 | I | By Reporting Person's Trust 2 | |
| Common Stock | holding | — | — | — | 500,000 | I | By Reporting Person's Trust 3 | |
| Common Stock | holding | — | — | — | 12,200 | I | By Trust 1 | |
| Common Stock | holding | — | — | — | 12,200 | I | By Trust 2 | |
| Common Stock | holding | — | — | — | 12,200 | I | By Trust 3 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $1.5068 | Nov 5, 2018 | M | 3,000 | D | — | Jun 3, 2025 | Common Stock | 3,000 | 105,254 | D |
Explanation of responses
- F1Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.
- F2This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person
- F3Represents the weighted average sale price of the shares sold ranging from $55.00 to $55.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F4Represents the weighted average sale price of the shares sold ranging from $56.15 to $57.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F5Represents the weighted average sale price of the shares sold ranging from $57.15 to $57.83 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F625% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date.